Results 11 to 20 of about 88,666 (249)
Chronic myelogenous leukemia on target [PDF]
Cancer Medicine, 2018 Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein.
Veronika Némethová, Filip Rázga
doaj +4 more sources
Chronic Myelogenous Leukemia [PDF]
Journal of the National Comprehensive Cancer Network, 2012 Chronic myelogenous leukemia (CML) is the one of the most common chronic myeloproliferative disorders. It has become the paradigmatic disease for molecular diagnosis and monitoring for several reasons: (1) CML has a unitary molecular definition, requiring the demonstration of the t(9;22)(q34;q11) chromosomal translocation or its product, the BCR-ABL ...
Susan, O'Brien +19 more
openaire +5 more sources
Myelogenous Leukemia in the Rat [PDF]
Blood, 1962 Abstract Observations on growth and other characteristics of subcutaneously transplanted chloroleukemia in non-inbred rats have been described in this report. This chloroleukemia cytologically is an acute or subacute, not chronic, myelogenous leukemia.
Andrew D. Dorr +3 more
openaire +3 more sources
ACUTE MYELOGENIC LEUKÆMIA [PDF]
The American Journal of the Medical Sciences, 1903 n ...
Billings, Frank, Capps, Joseph A.
openaire +3 more sources
Chronic Myelogenous Leukemia [PDF]
Hematology, 2002 Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Jorge E. Cortes +3 more
openaire +5 more sources
CHRONIC MYELOGENOUS LEUKAEMIA [PDF]
British Journal of Haematology, 2000 In the last decade, improvements in both non-transplant and transplant therapy have extended the lives of patients with CML, particularly those in chronic phase. The future will probably bring a greater understanding of molecular leukaemogenesis and options for treating CML. Non-transplant therapies in development include novel agents and
openaire +3 more sources
Acute myelogenous leukemia revealed by acute appendicitis
Apollo Medicine, 2020 Acute myelogenous leukemia can rarely involve the digestive tract. We report a case of a girl of 9 years old, admitted for surgical abdomen and operated for acute appendicitis. Complete blood count showed pancytopenia.
Sanae El Marzguioui +4 more
doaj +1 more source
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2015 Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille +2 more
doaj +1 more source
Preserved cellular immunity in smoldering acute leukemia [PDF]
, 1976 "Smoldering acute leukemia", a variant of acute myelogenous leukemia, has been recognized with frequent incidence in recent years. This is chracterized by benign clinical course, poor physical findings, leukopenia and mild anemia in the ...
Toki, Hironobu
core +1 more source